{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T09:12:09Z","timestamp":1760346729703},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.bcp.2018.10.024","type":"journal-article","created":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T02:11:26Z","timestamp":1540347086000},"page":"201-206","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Antiviral efficacy of the helicase-primase inhibitor amenamevir in murine models of severe herpesvirus infection"],"prefix":"10.1016","volume":"158","author":[{"given":"Kiyomitsu","family":"Katsumata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Chono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2018.10.024_b0005","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1146\/annurev.med.59.061606.095540","article-title":"Herpes simplex: insights on pathogenesis and possible vaccines","volume":"59","author":"Koelle","year":"2008","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bcp.2018.10.024_b0010","doi-asserted-by":"crossref","first-page":"22766","DOI":"10.3402\/jom.v5i0.22766","article-title":"Herpesviruses: latency and reactivation \u2013 viral strategies and host response","volume":"5","author":"Grinde","year":"2013","journal-title":"J. Oral Microbiol."},{"key":"10.1016\/j.bcp.2018.10.024_b0015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2018.10.024_b0020","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1086\/514600","article-title":"Herpes simplex viruses","volume":"26","author":"Whitley","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bcp.2018.10.024_b0025","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(00)04638-9","article-title":"Herpes simplex virus infections","volume":"357","author":"Whitley","year":"2001","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2018.10.024_b0030","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1086\/505359","article-title":"The cycle of human herpes simplex virus infection: virus transport and immune control","volume":"194","author":"Cunningham","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bcp.2018.10.024_b0035","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1469-0691.2005.01336.x","article-title":"Herpes simplex virus infection, with particular reference to the progression and complications of primary herpetic gingivostomatitis","volume":"12","author":"Kolokotronis","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.bcp.2018.10.024_b0040","series-title":"Fields Virology","first-page":"1823","article-title":"Herpes simplex viruses","author":"Roizman","year":"2013"},{"key":"10.1016\/j.bcp.2018.10.024_b0045","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3345\/kjp.2014.57.8.370","article-title":"Use of intravenous immunoglobulin in a disseminated varicella infection in an immunocompromised child","volume":"57","author":"Kim","year":"2014","journal-title":"Kor. J. Pediatr."},{"key":"10.1016\/j.bcp.2018.10.024_b0050","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/archinte.168.11.1137","article-title":"The treatment of herpes simplex infections: an evidence-based review","volume":"168","author":"Cernik","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.bcp.2018.10.024_b0055","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1001\/jama.1984.03340400031020","article-title":"Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial","volume":"251","author":"Reichman","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2018.10.024_b0060","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/infdis\/161.2.185","article-title":"Treatment of recurrent herpes simplex labialis with oral acyclovir","volume":"161","author":"Spruance","year":"1990","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bcp.2018.10.024_b0065","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nm0402-327","article-title":"New anti-HSV therapeutics target the helicase-primase complex","volume":"8","author":"Crumpacker","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2018.10.024_b0070","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/QCO.0000000000000288","article-title":"Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management","volume":"29","author":"Piret","year":"2016","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.bcp.2018.10.024_b0075","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nm0402-386","article-title":"Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease","volume":"8","author":"Crute","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2018.10.024_b0080","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm0402-392","article-title":"New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease","volume":"8","author":"Kleymann","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2018.10.024_b0085","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/jac\/dkq198","article-title":"ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2","volume":"65","author":"Chono","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bcp.2018.10.024_b0090","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.antiviral.2012.12.006","article-title":"Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus","volume":"97","author":"Chono","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2018.10.024_b0095","doi-asserted-by":"crossref","first-page":"7210","DOI":"10.3390\/molecules16097210","article-title":"Effect of ASP2151, a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes","volume":"16","author":"Katsumata","year":"2011","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2018.10.024_b0100","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1128\/AAC.01803-12","article-title":"Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection","volume":"57","author":"Katsumata","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2018.10.024_b0105","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/1346-8138.13948","article-title":"i. Study, Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: a randomized, double-blind, valaciclovir-controlled phase 3 study","volume":"44","author":"Kawashima","year":"2017","journal-title":"J. Dermatol."},{"key":"10.1016\/j.bcp.2018.10.024_b0110","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1128\/AAC.39.5.1114","article-title":"Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model","volume":"39","author":"Field","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2018.10.024_b0115","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/510206","article-title":"Recommendations for the management of herpes zoster","volume":"44","author":"Dworkin","year":"2007","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl 4","key":"10.1016\/j.bcp.2018.10.024_b0120","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/ajt.12105","article-title":"Herpes simplex virus in solid organ transplantation","volume":"13","author":"Wilck","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.bcp.2018.10.024_b0125","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1128\/CMR.16.1.114-128.2003","article-title":"Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy","volume":"16","author":"Bacon","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.bcp.2018.10.024_b0130","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.idc.2010.01.001","article-title":"Antiviral drug resistance: mechanisms and clinical implications","volume":"24","author":"Strasfeld","year":"2010","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.bcp.2018.10.024_b0135","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1128\/JCM.38.7.2568-2573.2000","article-title":"Quantitation of varicella-zoster virus DNA in whole blood, plasma, and serum by PCR and electrochemiluminescence","volume":"38","author":"de Jong","year":"2000","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.bcp.2018.10.024_b0140","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2016.12.008","article-title":"Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor","volume":"139","author":"Yajima","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2018.10.024_b0145","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1128\/AAC.46.6.1766-1772.2002","article-title":"Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293","volume":"46","author":"Betz","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2018.10.024_b0150","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/QCO.0000000000000211","article-title":"Herpes simplex virus and varicella zoster virus: recent advances in therapy","volume":"28","author":"De","year":"2015","journal-title":"Curr. Opin. Infect. Dis."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218304519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218304519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T22:27:37Z","timestamp":1605306457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295218304519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":30,"alternative-id":["S0006295218304519"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2018.10.024","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral efficacy of the helicase-primase inhibitor amenamevir in murine models of severe herpesvirus infection","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2018.10.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}